CTNNB1 and Miyoshi myopathy: However, analysis of a separate, clinicopathologically annotated, multi-institutional cohort of patients with MM suggests that patients with APC/CTNNB1 genetic aberrations have a similar benefit from immunotherapies compared to patients without.